Catherine Shaffer

Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.

The firm hopes to develop its DeepHRD digital pathology test as an alternative to costly companion diagnostics based on next-generation sequencing.

The test combining DNA fragmentomics and protein biomarkers had sensitivity ranging from 72 percent to 100 percent for detection of ovarian cancer, depending on disease stage.

The company recently published data on the MESA platform's ability to screen for colorectal cancer and is considering other testing opportunities.

Researchers hope their study will show that tests for gene variants and DNA methylation can predict which lower-risk patients may be cured without a stem cell transplant.

The new microfluidic chip is designed to capture more circulating tumor cells in patients with non-small cell lung cancer than currently available technologies.

The firm hopes that Medicare coverage will facilitate patient access to the NavDx test and spur its inclusion in practice guidelines for head and neck cancer.

At AACR, a study explored the impact of a chain of default notifications in prompting physician referrals and patient adoption of genetic testing in colorectal cancer patients.

UPitt is hoping the latest data demonstrating the utility of its 22-gene PancreaSeq test will help drive adoption and reimbursement.

The Consortium for Analytic Standardization hopes to bring an archaic technology into the 21st century by producing calibrated standards for the most utilized IHC-based biomarker tests.